Shilpa Medicare Limited (NSE: SHILPAMED) stock price gains 5% intraday, clearing its 6M resistance trendline and entering a breakout phase. .
Shilpa Medicare Limited (NSE: SHILPAMED) acquires 30.4% stake in Gate2Brain to advance brain cancer therapy.
Shilpa Medicare Limited (SHILPAMED) reports Q4 FY26 earnings with revenue up 30% and EBITDA surging 40%.